Immunotherapy of Cancer

Published by: BCC Research

Published: Mar. 30, 2007 - 192 Pages

Table of Contents

INTRODUCTION

CONTRIBUTION OF THE STUDY AND FOR WHOM

OBJECTIVES AND GOALS OF THE STUDY

STUDY SCOPE AND FORMAT

METHODOLOGY

INFORMATION SOURCES

AUTHOR’S CREDENTIALS

RELATED BCC WORK CREDENTIALS INCLUDING WORK DONE

BY OTHER AUTHORS

BCC ONLINE SERVICES

DISCLAIMER

EXECUTIVE SUMMARY

SUMMARY TABLE GLOBAL MARKET FORECAST FOR

IMMUNOTHERAPIES TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)

SUMMARY FIGURE GLOBAL MARKET FORECAST FOR

IMMUNOTHERAPIES TO TREAT CANCER, 2005-2012 ($ MILLIONS)

OVERVIEW

DEFINITION AND ETIOLOGY OF Cancer

CANCER STATISTICS

TABLE 1 PROBABILITY OF DEVELOPING SELECTED INVASIVE CANCERS, BY SEX, BASED ON CANCER CASES DIAGNOSED IN 2000 AND 2002 (%)

TABLE 2 INCIDENCE, MORTALITY AND SURVIVAL RATES FOR COMMON CANCERS IN THE U.S., 2006

TABLE 3 CANCER PREVALENCE RATES IN THE U.S., 2003*

TABLE 3 (CONTINUED)

IMMUNOTHERAPY OF CANCER

TYPES OF CANCER FOR WHICH IMMUNOTHERAPY

TREATMENTS EXIST OR ARE LIKELY TO BE INTRODUCED BY 2012

BREAST CANCER

COLORECTAL CANCER

HEAD AND NECK CANCER

KIDNEY CANCER

LEUKEMIAS

Leukemias (Continued)

LIVER CANCER

LUNG CANCER

MALIGNANT MELANOMA

MULTIPLE MYELOMA

NONHODGKIN’S LYMPHOMA

OSTEOSARCOMA

OVARIAN CANCER

PANCREATIC CANCER

PROSTATE CANCER

STOMACH CANCER

CURRENT METHODS OF TREATMENT

SURGERY

RADIATION THERAPY

PHARMACEUTICAL THERAPY

IMMUNOTHERAPY

INFLAMMATORY RESPONSE

Cell-Mediated Immunity

Humoral Immunity

Macrophage Processing

Nonspecific Immunity

CYTOKINES

Two Types of Cytokines

MONOCYTES

PHAGOCYTES

SPECIFIC IMMUNITY

Lymphocytes

B-Cells

T-Cells

NK Cells

CLINICAL APPROACHES TO IMMUNOTHERAPY

Passive Cellular Immunotherapy

Dealing with Significant Toxicity

Passive Humoral Immunotherapy

Active Specific Immunotherapy

Nonspecific Immunotherapy

TYPES OF IMMUNOTHERAPY PRODUCTS

Biological Response Modifiers

TABLE 4 COLONY STIMULATING FACTORS AND ERYTHROPOIETIN, THEIR NATURAL SOURCES AND MAJOR EFFECTS

TABLE 5 INTERFERONS, THEIR NATURAL SOURCES AND MAJOR EFFECTS

TABLE 6 INTERLEUKINS, THEIR NATURAL SOURCES AND MAJOR EFFECTS

TABLE 6 (CONTINUED)

TABLE 7 TUMOR NECROSIS FACTORS, THEIR NATURAL SOURCES, AND MAJOR EFFECTS

Colony Stimulating Factors

Treating Neutropenic Fevers

A Justified Expense

Interferons

A Family of Small Proteins

Anticancer Effects

Side Effects

Production of Interferon

Interferon-alpha

Interferon-beta

Interferon-Beta-1a

Interleukins

Interleukin-2

Other Infection-Fighting Cells

Side Effects

Tumor Necrosis Factor

ANTIBODIES

ANTIBODY FORMS IN PRODUCTS

Abtides

Antibody Conjugates

Antiserums

Bispecific Antibodies

Camouflaged Antibodies

Chimeric Antibodies

Humanized Antibodies

Fully Human Antibodies

Progenitor Stem Cells

Single-Chain Antibodies

Synthetic Antibodies

VACCINES

ANTIGENS: THEIR ROLE IN CANCER VACCINES

VACCINE DEVELOPMENT STRATEGIES

A SUMMARY OF TWO APPROACHES: LOW-TECH VS. HIGHTECH

TECHNOLOGY ADVANCES

PRODUCTS AND APPLICATIONS

IMMUNOTHERAPY PRODUCTS FOR THE TREATMENT OF CANCER INTRODUCED IN 2004, 2005 AND 2006

TABLE 8 IMMUNOTHERAPY PRODUCTS FOR THE TREATMENT OF CANCER INTRODUCED IN 2004, 2005 AND 2006

MECHANISM OF ACTION OF SELECTED IMMUNOTHERAPY PRODUCTS

TABLE 9 MOLECULAR TARGET(S), MECHANISM(S) OF ACTION AND CANCER(S) TARGETED BY LEADING IMMUNOTHERAPY PRODUCTS

BIOLOGICAL RESPONSE MODIFIERS

THE MARKET FOR BIOLOGICAL RESPONSE MODIFIERS TO TREAT CANCER

TABLE 10 GLOBAL MARKET FORECAST FOR BIOLOGICAL RESPONSE MODIFIERS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)

FIGURE 1 GLOBAL MARKET FORECAST FOR BIOLOGICAL RESPONSE MODIFIERS TO TREAT CANCER, 2005-2012 ($ MILLIONS)

COLONY STIMULATING FACTORS

MARKETED BRM PRODUCTS FOR THE TREATMENT OF CANCER

TABLE 11 COLONY-STIMULATING FACTOR PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER

Aranesp

Granocyte

Leukine

Neorecormon

Neulasta/Neupopeg/Neupogen/Granulokine

Neumega

Procrit

Stemgen

The Market for Colony Stimulating Factors

TABLE 12 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS IN CANCER TREATMENT BY PRODUCT, THROUGH 2012 ($ MILLIONS)

The Market for Colony Stimulating Factors to Treat

Cancer

TABLE 13 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)

FIGURE 2 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)

Colony Stimulating Factors in Development

INTERFERONS

Interferon-Alpha

Interferon Alpha-2b Products

Marketed Interferon Products for the Treatment of

Cancer

TABLE 14 INTERFERON PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER

Infergen

Intron A and PEG-Intron/Rebetron

 PEG-Intron vs. Intron A

Multiferon

Roferon-A

Interferon-Gamma

Actimmune/Imukin

The Market for Interferon Products Used in the

Treatment of Cancer

TABLE 15 GLOBAL MARKET FORECAST FOR INTERFERON ALPHA AND GAMMA PRODUCTS* USED IN THE TREATMENT OF CANCER BY PRODUCT, THROUGH 2012 ($ MILLIONS)

THE MARKET FOR INTERFERONS TO TREAT CANCER

TABLE 16 GLOBAL MARKET FORECAST FOR INTERFERONS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)

FIGURE 3 GLOBAL MARKET FORECAST FOR INTERFERONS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)

INTERLEUKINS

Marketed Interleukin Products for the Treatment of

Cancer

TABLE 17 INTERLEUKIN PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER

ONTAK

PROLEUKIN

The Market for Interleukin Products for the Treatment of

Cancer

TABLE 18 GLOBAL MARKET FORECAST FOR INTERLEUKINS IN THE TREATMENT OF CANCER, BY PRODUCT, THROUGH 2012 ($ MILLIONS)

Product

TUMOR NECROSIS FACTOR INHIBITORS

BIOLOGICAL RESPONSE MODIFIERS IN DEVELOPMENT FOR THE TREAMENT OF CANCER

TABLE 19 SELECTED BIOLOGICAL RESPONSE MODIFIERS IN PHASE III OR LATER DEVELOPMENT

Actimmune

Cintrekedin Besudotox

Multikine

Clinical Trial Results

A Coca-Cola Formula

PEG-Intron

PRX321

Virulizin

COMBINATION CYTOKINE-ANTIBODY TECHNOLOGY IN DEVELOPMENT

MONOCLONAL ANTIBODY PRODUCTS

TABLE 20 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF CANCER: U.S.

TABLE 20 (CONTINUED)

MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF CANCER

Avastin

Avastin (Continued)

Avastin (Continued)

The Avastin Advantage

Medicare Reimbursement Law Supports Use of

Avastin

Bexxar

Bexxar (Continued)

Campath/MabCampath

Erbitux

TABLE 21 RANGE OF EGFR EXPRESSION IN SOLID TUMORS

TABLE 22 EGFR IN PROGNOSIS FOR SELECTED TUMOR TYPES

Erbitux (Continued)

Herceptin

Mylotarg

Panorex

Rituxan/MabThera

Rituxan/Mabthera (Continued)

Vectibix

Zevalin

First Radioimmunotherapeutic Drug

Results of Trials

Sales of Zevalin

THE MARKET FOR MONOCLONAL ANTIBODY PRODUCTS FOR ALL INDICATIONS

Monoclonal Antibody Sales by Technology

TABLE 23 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY, THROUGH 2012 ($ MILLIONS)

FIGURE 4 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY, 2005-2012 ($ MILLIONS)

Monoclonal Antibody Sales by Target

TABLE 24 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TARGET, THROUGH 2012 ($ MILLIONS)

THE MARKET FOR THERAPEUTIC MONOCLONAL

ANTIBODIES TO TREAT CANCER

TABLE 25 GLOBAL MARKET FORECAST FOR MONOCLONAL ANTIBODY PRODUCTS FOR CANCER TREATMENT, THROUGH 2012 ($ MILLIONS)

TABLE 25 (CONTINUED)

THE EUROPEAN MARKET FOR THERAPEUTIC

MONOCLONAL ANTIBODIES

TABLE 26 MONOCLONAL ANTIBODY PRODUCTS ON THE EUROPEAN MARKET FOR THE TREATMENT OF CANCER

TABLE 27 EUROPEAN MARKET FOR MONOCLONAL ANTIBODY PRODUCTS FOR CANCER TREATMENT, THROUGH 2012 ($ MILLIONS)

FIGURE 5 EUROPEAN MARKET FOR MONOCLONAL ANTIBODY PRODUCTS FOR CANCER TREATMENT, 2005-2012 ($ MILLIONS)

MONOCLONAL ANTIBODY PRODUCTS IN DEVELOPMENT

FOR THE treatment of cancer

TABLE 28 SELECTED MONOCLONAL ANTIBODY PRODUCTS IN PHASE III OR LATER DEVELOPMENT FOR THE TREATMENT OF CANCER

TABLE 28 (CONTINUED)

TABLE 28 (CONTINUED)

Abegrin (formerly Vitaxin)

Avastin

Campath/MabCampath

CP-675,206

Denosumab

Herceptin

HuMax-CD4

HuMax-CD20

HuMax-EGFr

MDX-010

Nimotuzumab

OvaRex

Pemtumomab

Rencarex

Rituxan/MabThera

VACCINES

TABLE 29 TUMOR ANTIGENS USED IN CANCER VACCINES

TYPES OF CANCER VACCINES

Whole-cell Vaccines

Antigen/Adjuvant Vaccines

Idiotype Vaccines

Autologous versus Allogenic Vaccines

Dendritic Cell Vaccines

Synthetic Cell Protein Antigens

Gangliosides

Heat Shock Proteins

CANCER VACCINES ON THE WORLDWIDE MARKET

Gardasil

M-Vax

Melacine

OncoVax

THE MARKET FOR CANCER VACCINES

TABLE 30 ESTIMATED U.S. MARKET FOR CANCER VACCINES BY INDICATION

TABLE 31 GLOBAL MARKET FORECAST FOR CANCER VACCINES, BY TECHNOLOGY, THROUGH 2012 ($ MILLIONS)

FIGURE 6 PERCENTAGE OF GLOBAL MARKET HELD BY AUTOLOGOUS VERSUS ALLOGENEIC CANCER VACCINES, 2007 AND 2012 (%)

CANCER VACCINES IN DEVELOPMENT

TABLE 32 SELECTED CANCER VACCINES IN PHASE III OR LATER TRIALS

TABLE 32 (CONTINUED)

TABLE 33 TYPES OF VACCINES IN DEVELOPMENT FOR CANCER TREATMENT

Allovectin-7

Allovectin-7 (Continued)

BiovaxID

Cervarix

DCVax-Brain

DCVax-Prostate

GMK

GVAX Prostate Vaccine

IGN101

Insegia

Insegia (Continued)

Insegia (Continued)

M-Vax

Melacine

MyVax Personalized Immunotherapy

Myvax Personalized … (Continued)

Oncophage

OncoVax

Panvac-VF

Sipuleucel-T

Stimuvax

TG 4001

TG 1042

Theratope

OTHER IMMUNOTHERAPY PRODUCTS FOR THE TREATMENT OF CANCER

MARKETED PRODUCTS

Gleevec

Iressa

Nexavar

Revlimid

Sprycel

Sutent

Tarceva

Thalomid

Velcade

The Market for Other Immunotherapy Products for the

Treatment of Cancer

TABLE 34 GLOBAL MARKET FORECAST FOR OTHER CANCER TREATMENT IMMUNOTHERAPY PRODUCTS, THROUGH 2012 ($ MILLIONS)

PRODUCTS IN DEVELOPMENT FOR THE TREATMENT OF CANCER

TABLE 35 OTHER IMMUNOTHERPAY PRODUCTS IN PHASE III OR LATER DEVELOPMENT FOR THE TREATMENT OF CANCER

TABLE 28 (CONTINUED)

TABLE 28 (CONTINUED)

Advexin

BAY 43-9006

Ceplene

Dacogen

Efaproxyn

Genasense

Hycamptin

INGN 241

Junovan

Nexavar

Onconase

Orathecin

Pixantrone

PTK787

Telcyta

Thymitaq

Torisel

Tykerb/Tycerb

Velcade

Zarnestra

Zarnestra (Continued)

INDUSTRY

BLOCKBUSTER DRUGS ON THE WORLDWIDE

PHARMACEUTICAL MARKET APPROACH 100

U.S. PHARMACEUTICAL INDUSTRY GROWTH TO INCREASE SLIGHTLY

MORE MERGERS, ACQUISITIONS AND LICENSING

MORE MERGERS, ACQUISITIONS AND … (Continued)

BIOGENERICS—THE NEXT REVOLUTION

BIOGENERICS—THE NEXT … (Continued)

COMPANY PROFILES

ABGENIX, INC.

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

XenoMouse and XenoMax Technologies

Technology Advantages

Technology Advantages (Continued)

CORPORATE STRATEGY

ALFACELL CORPORATION

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

CORPORATE STRATEGY

AMGEN, INC.

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

TABLE 36 AMGEN’S PRODUCTS IN PHASE II OR LATER DEVELOPMENT

CORPORATE STRATEGY

ANTIGENICS INC

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

TABLE 37 ANTIGENICS’ PRODUCT PIPELINE

CORPORATE STRATEGY

AVAX TECHNOLOGIES, INC

BUSINESS OVERVIEW

PRODUCTS

CORPORATE STRATEGY

BIOGEN IDEC, INC

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

CORPORATE STRATEGY

BIOMIRA INC

EDMONTON R&D PARK

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

CORPORATE STRATEGY

CHIRON CORPORATION

BUSINESS OVERVIEW

FINANCIAL INFORMATION

LEADING PRODUCTS

CORPORATE STRATEGY

GENENTECH, INC.

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

CORPORATE STRATEGY

TABLE 38 SELECTED PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES

TABLE 38 (CONTINUED)

TABLE 39 SELECTED ADDITIONAL PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES

GENMAB A/S

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

CORPORATE STRATEGY

GENZYME CORPORATION

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

CORPORATE STRATEGY

GLAXOSMITHKLINE PLC

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

IMCLONE SYSTEMS, INC

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

TABLE 40 IMCLONE SYSTEMS’ PRODUCT PIPELINE

CORPORATE STRATEGY

IMMUNOMEDICS, INC

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

TABLE 41 IMMUNOMEDICS’ THERAPEUTIC PRODUCT PIPELINE

TABLE 41 (CONTINUED)

CORPORATE STRATEGY

MEDAREX, INC.

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

TABLE 42 MEDAREX’S PRODUCT PIPELINE

CORPORATE STRATEGY

MEDIMMUNE, INC.

BUSINESS OVERVIEW

FINANCIAL INFORMATION

LEADING PRODUCTS

Leading Products (Continued)

TABLE 43 MEDIMMUNE’S PRODUCTS IN PHASE II OR LATER DEVELOPMENT

CORPORATE STRATEGY

MERCK & COMPANY, INC

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

CORPORATE STRATEGY

MILLENNIUM PHARMACEUTICALS, INC

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

TABLE 44 MILLENNIUM’S PRODUCTS IN PHASE II OR LATER DEVELOPMENT

CORPORATE STRATEGY

NORTHWEST BIOTHERAPEUTICS, INC

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

TABLE 45 NORTHWEST BIOTHERAPEUTICS’ PRODUCT PIPELINE

CORPORATE STRATEGY

PFIZER CORPORATION

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

CORPORATE STRATEGY

Corporate Strategy (Continued)

PROGENICS PHARMACEUTICALS, INC.

BUSINESS OVERVIEW

FINANCIAL INFORMATION

LEADING PRODUCTS

TABLE 46 PROGENICS’ PRODUCT PIPELINE

CORPORATE STRATEGY

PROTEIN DESIGN LABS

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

TABLE 47 PROTEIN DESIGN LABS’ PRODUCTS IN PHASE II OR LATER

CORPORATE STRATEGY

TRANSGENE S/A

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

CORPORATE STRATEGY

VIREXX MEDICAL CORPORATION

BUSINESS OVERVIEW

FINANCIAL INFORMATION

PRODUCTS

CORPORATE STRATEGY

LIST OF TABLES

SUMMARY TABLE GLOBAL MARKET FORECAST FOR IMMUNOTHERAPIES TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)

TABLE 1 PROBABILITY OF DEVELOPING SELECTED INVASIVE CANCERS, BY SEX, BASED ON CANCER CASES DIAGNOSED IN 2000 AND 2002 (%)

TABLE 2 INCIDENCE, MORTALITY AND SURVIVAL RATES FOR COMMON CANCERS IN THE U.S., 2006

TABLE 3 CANCER PREVALENCE RATES IN THE U.S., 2003*

TABLE 4 COLONY STIMULATING FACTORS AND ERYTHROPOIETIN, THEIR NATURAL SOURCES AND MAJOR EFFECTS

TABLE 5 INTERFERONS, THEIR NATURAL SOURCES AND MAJOR EFFECTS

TABLE 6 INTERLEUKINS, THEIR NATURAL SOURCES AND MAJOR EFFECTS

TABLE 7 TUMOR NECROSIS FACTORS, THEIR NATURAL SOURCES, AND MAJOR EFFECTS

TABLE 8 IMMUNOTHERAPY PRODUCTS FOR THE TREATMENT OF CANCER INTRODUCED IN 2004, 2005 AND 2006

TABLE 9 MOLECULAR TARGET(S), MECHANISM(S) OF ACTION AND CANCER(S) TARGETED BY LEADING IMMUNOTHERAPY PRODUCTS

TABLE 10 GLOBAL MARKET FORECAST FOR BIOLOGICAL RESPONSE MODIFIERS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)

TABLE 11 COLONY-STIMULATING FACTOR PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER

TABLE 12 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS IN CANCER TREATMENTBY PRODUCT, THROUGH 2012 ($ MILLIONS)

TABLE 13 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)

TABLE 14 INTERFERON PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER

TABLE 15 GLOBAL MARKET FORECAST FOR INTERFERON ALPHA AND GAMMA PRODUCTS* USED IN THE TREATMENT OF CANCER BY PRODUCT, THROUGH 2012 ($ MILLIONS)

TABLE 16 GLOBAL MARKET FORECAST FOR INTERFERONS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)

TABLE 17 INTERLEUKIN PRODUCTS ON THE MARKET FOR THE TREATMENT OF CANCER

TABLE 18 GLOBAL MARKET FORECAST FOR INTERLEUKINS IN THE TREATMENT OF CANCER, BY PRODUCT, THROUGH 2012 ($ MILLIONS)

TABLE 19 SELECTED BIOLOGICAL RESPONSE MODIFIERS IN PHASE III OR LATER DEVELOPMENT

TABLE 20 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF CANCER: U.S.

TABLE 21 RANGE OF EGFR EXPRESSION IN SOLID TUMORS

TABLE 22 EGFR IN PROGNOSIS FOR SELECTED TUMOR TYPES

TABLE 23 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY, THROUGH 2012 ($ MILLIONS)

TABLE 24 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TARGET, THROUGH 2012 ($ MILLIONS)

TABLE 25 GLOBAL MARKET FORECAST FOR MONOCLONAL

ANTIBODY PRODUCTS FOR CANCER TREATMENT, THROUGH 2012 ($ MILLIONS)

TABLE 26 MONOCLONAL ANTIBODY PRODUCTS ON THE EUROPEAN MARKET FOR THE TREATMENT OF CANCER

TABLE 27 EUROPEAN MARKET FOR MONOCLONAL ANTIBODY PRODUCTS FOR CANCER TREATMENT, THROUGH 2012 ($ MILLIONS)

TABLE 28 SELECTED MONOCLONAL ANTIBODY PRODUCTS IN PHASE III OR LATER DEVELOPMENT FOR THE TREATMENT OF CANCER

TABLE 29 TUMOR ANTIGENS USED IN CANCER VACCINES

TABLE 30 ESTIMATED U.S. MARKET FOR CANCER VACCINES BY INDICATION

TABLE 31 GLOBAL MARKET FORECAST FOR CANCER VACCINES, BY TECHNOLOGY, THROUGH 2012 ($ MILLIONS)

TABLE 32 SELECTED CANCER VACCINES IN PHASE III OR LATER TRIALS

TABLE 33 TYPES OF VACCINES IN DEVELOPMENT FOR CANCER TREATMENT

TABLE 34 GLOBAL MARKET FORECAST FOR OTHER CANCER

TREATMENT IMMUNOTHERAPY PRODUCTS, THROUGH 2012 ($ MILLIONS)

TABLE 35 OTHER IMMUNOTHERPAY PRODUCTS IN PHASE III OR LATER DEVELOPMENT FOR THE TREATMENT OF CANCER

TABLE 36 AMGEN’S PRODUCTS IN PHASE II OR LATER DEVELOPMENT

TABLE 37 ANTIGENICS’ PRODUCT PIPELINE

TABLE 38 SELECTED PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES

TABLE 39 SELECTED ADDITIONAL PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES

TABLE 40 IMCLONE SYSTEMS’ PRODUCT PIPELINE

TABLE 41 IMMUNOMEDICS’ THERAPEUTIC PRODUCT PIPELINE

TABLE 42 MEDAREX’S PRODUCT PIPELINE

TABLE 43 MEDIMMUNE’S PRODUCTS IN PHASE II OR LATER DEVELOPMENT

TABLE 44 MILLENNIUM’S PRODUCTS IN PHASE II OR LATER DEVELOPMENT

TABLE 45 NORTHWEST BIOTHERAPEUTICS’ PRODUCT PIPELINE

TABLE 46 PROGENICS’ PRODUCT PIPELINE

TABLE 47 PROTEIN DESIGN LABS’ PRODUCTS IN PHASE II OR LATER

LIST OF FIGURES

SUMMARY FIGURE GLOBAL MARKET FORECAST FOR IMMUNOTHERAPIES TO TREAT CANCER, 2005-2012 ($ MILLIONS)

FIGURE 1 GLOBAL MARKET FORECAST FOR BIOLOGICAL

RESPONSE MODIFIERS TO TREAT CANCER, 2005-2012 ($ MILLIONS)

FIGURE 2 GLOBAL MARKET FORECAST FOR COLONY STIMULATING FACTORS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)

FIGURE 3 GLOBAL MARKET FORECAST FOR INTERFERONS TO TREAT CANCER, THROUGH 2012 ($ MILLIONS)

FIGURE 4 GLOBAL MARKET FORECAST FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY, 2005-2012 ($ MILLIONS)

FIGURE 5 EUROPEAN MARKET FOR MONOCLONAL ANTIBODY PRODUCTS FOR CANCER TREATMENT, 2005-2012 ($ MILLIONS)

FIGURE 6 PERCENTAGE OF GLOBAL MARKET HELD BY

AUTOLOGOUS VERSUS ALLOGENEIC CANCER VACCINES, 2007 AND 2012 (%)

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.